Tradr 2X Long Cbrs Daily ETF (CBRX)

Columbia Laboratories, Inc. is in the business of developing, manufacturing and selling pharmaceutical products that utilize its proprietary bioadhesive drug delivery technologies to treat various medical conditions. It is focused in developing drugs that improve treatment options for women's health, an area where it have a rich heritage and proven capabilities. It has developed and brought to market five bioadhesive vaginal gel products that provide patient-friendly solutions for infertility, pregnancy support, amenorrhea, and other gynecologic conditions. The Company's Progesterone Products include CRINONE and PROCHIEVE. CRINONE is a sustained release gel that delivers natural progesterone vaginally. CRINONE utilizes the Company's patented BDS, which enables the progesterone to achieve a preferential uptake of drug from the vagina to the uterus, or a "First Uterine Pass Effect." The product is available in both 4% and 8% concentrations, and in the U.S. is also known under the trade name PROCHIEVE. CRINONE is sold outside the U.S. by Merck Serono under a worldwide (excluding the U.S.) license from the Company. Products Outside of the Women's Health Market include STRIANT which utilizes the BDS to achieve controlled and sustained delivery of testosterone via the buccal cavity - the small depression in the mouth where the gum meets the upper lip above the incisor teeth. STRIANT is absorbed into the bloodstream and delivers testosterone directly into the superior vena cava (major blood vessel), bypassing the gastrointestinal system and liver. All of the products it has developed utilize its Bioadhesive Delivery System ("BDS"), which consists mainly of a polymer (polycarbophil) and an active ingredient. The BDS is based upon the principle of bioadhesion, a process by which the polymer adheres to epithelial surfaces or mucosa. Its vaginal products adhere to the vaginal epithelium; the buccal products adhere to the mucosal membrane of the gum and cheek. The polymer remains attached to epithelial surfaces or mucosa and is discharged upon normal cell turnover, a physiological process that, depending upon the area of the body, occurs every 12 to 72 hours, or longer. Both vaginal and buccal BDS products provide sustained and controlled delivery of active drug ingredients. Its extended period of attachment permits use of BDS in products when extended duration of effectiveness is desirable or required. It is substantially dependent on three third-party manufacturers for the products that it sell to marketing partners in the U.S. and around the world. It's CRINONE and PROCHIEVE vaginal gel products are manufactured in bulk by Fleet Laboratories Limited, Watford, Herts, United Kingdom ("Fleet") and filled into overwrapped single-use disposable applicators by Maropack AG, Zell, Switzerland ("Maropack"). The company's customers include trade customers, such as drug wholesalers, specialty pharmacies, and chain drug stores, and its marketing partners. The Company and its marketing partners compete against established pharmaceutical and consumer product companies which market products addressing similar needs.